BrainSpec, the web-based software platform that intends to use existing MRI machines to enable virtual biopsies of the brain, has received FDA designation as a breakthrough device for estimating isocitrate dehydrogenase (IDH) status in glioma patients in whom biopsy is inadvisable.
Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.
